Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma

Background: Present guidelines recommend a life-long therapy with mepolizumab in patients suffering from severe eosinophilic asthma as several studies proved the disadvantages of treatment cessation. This study evaluated the possibility of extending the dosage intervals of mepolizumab in those patie...

Full description

Bibliographic Details
Main Authors: Georg Bölke, MD, Xunliang Tong, MD, Torsten Zuberbier, MD, PhD, Jean Bousquet, MD, PhD, Karl-Christian Bergmann, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-10-01
Series:World Allergy Organization Journal
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455122000795